What Is Follistatin-344? The Myostatin-Binding Protein
What is follistatin, and where does the "344" come from?
Follistatin is a naturally produced protein that regulates the activin/myostatin signaling family, part of the broader TGF-beta superfamily involved in endocrine, metabolic, and immune regulation (Nicholson et al., 2004). The gene produces two splice variants through alternative mRNA processing: follistatin-315 and follistatin-288, with follistatin-344 being the full-length precursor form that retains a heparin-binding domain absent in the shorter variant. That heparin-binding domain lets follistatin-344 attach to cell surfaces and the extracellular matrix near the tissue where it's produced, giving it more localized activity than the circulating, unbound follistatin-315.
This distinction matters for anyone comparing the two forms. It is covered in more depth on our Follistatin-344 vs Follistatin-315 comparison page.
What does follistatin actually do in the body?
Follistatin's primary documented role is binding and inhibiting myostatin (GDF-8) and related activins, which act as negative regulators of skeletal muscle mass. When myostatin signaling is blocked, animal models show increased muscle fiber growth and reduced muscle wasting (Rodino-Klapac et al., 2009; Kota et al., 2009). The mechanism has been studied as a potential therapeutic target across muscle-wasting conditions including Duchenne and Becker muscular dystrophy, Pompe disease, and inclusion body myositis (Mendell et al., 2015; Kastrinaki & Lawlor, 2010; Mendell et al., 2017).
A fuller explanation of the myostatin pathway itself, including why blocking it is a rational therapeutic idea in dystrophies, is on our mechanism page.
Why do bodybuilding forums talk about Follistatin-344?
The logic on forums is straightforward: if myostatin normally caps muscle growth, and follistatin blocks myostatin, then more follistatin should mean more muscle. That reasoning is not wrong as a mechanism description. It is wrong as a leap to "therefore an injectable peptide will build muscle in a healthy adult," because the studies supporting that mechanism used gene-delivery vectors, not the short synthetic Follistatin-344 peptide sold online, and were conducted in mice or in small clinical dystrophy trials, not in healthy people using it for performance.
The most rigorous human data available are from a phase 1/2a gene therapy trial in Becker muscular dystrophy patients using AAV-delivered follistatin, not an injected peptide, and even that trial was small and disease-specific (Mendell et al., 2015; Mendell et al., 2017). There is no published trial of synthetic Follistatin-344 peptide injections in healthy adults for hypertrophy. Our evidence quality page breaks down what these studies did and did not measure.
Is there any human evidence for Follistatin-344 specifically as an injectable?
Not that meets a clinical evidence standard. The published literature on follistatin as a muscle-building intervention is built on:
- Mouse models of muscular dystrophy and Pompe disease treated with viral vectors expressing follistatin, not synthetic peptide (Nakatani et al., 2008; Kastrinaki & Lawlor, 2010)
- Myoblast transplantation studies in dystrophic mice (Benabdallah et al., 2008; Rousseau et al., 2009)
- Small human gene therapy trials in Becker muscular dystrophy and inclusion body myositis patients, delivered via intramuscular AAV injection under IRB and FDA-regulated protocols, not as an over-the-counter peptide (Mendell et al., 2015; Mendell et al., 2017)
None of this constitutes evidence that a self-administered synthetic Follistatin-344 peptide is safe or effective for muscle growth in a healthy person. The distance between "myostatin inhibition helps dystrophic mice" and "injecting this peptide will safely build muscle in a gym-goer" is the single biggest thing forum discussion glosses over.
What is Follistatin-344's regulatory status?
Follistatin-344 has no FDA-approved use for any indication, human or otherwise. It is not on the FDA's 503A bulk drug substances list, meaning it does not have a recognized pathway for compounding pharmacies to legally prepare it as a compounded drug under that section of the FD&C Act (FDA 503A bulk substances list). Products sold as "Follistatin-344" online are typically marketed as research chemicals, not as drugs intended for human use, which is a labeling distinction, not a safety certification.
For a live, dated view of where Follistatin-344 and related peptides stand regulatory-wise, see the FDA Peptide Status Tracker and our dedicated FDA status page.
What are the known safety concerns?
Because there is no human safety data for injected Follistatin-344 peptide specifically, safety concerns are inferred from what is known about disrupting the activin/myostatin/follistatin axis broadly, which affects more than muscle. Follistatin and activin signaling are involved in reproductive tract development and function (Oduwole et al., 2017), cardiac stress responses in heart failure models (Wang et al., 2017), and fibrosis regulation (Wang et al., 2017). Disrupting a signaling system that touches reproductive, cardiac, and fibrotic pathways carries plausible off-target risk even though no injectable-peptide-specific adverse event data exists to quantify it. A detailed risk breakdown is on our side effects and risks page.
Evidence boundary: what's established, what's plausible, what's not known
Established: Follistatin binds and inhibits myostatin and activin signaling; this is well-documented mechanistic and animal-model biology across two decades of research. AAV-delivered follistatin gene therapy has been tested in small human trials for specific muscle-wasting diseases with some functional improvement reported.
Plausible but unproven: That myostatin inhibition via this pathway could theoretically increase muscle mass in healthy humans, based on the animal mechanism, though this has not been tested in healthy adults with the synthetic peptide.
Not established: The safety, dosing, pharmacokinetics, or efficacy of synthetic Follistatin-344 peptide self-injection in healthy people for hypertrophy or performance. No published human trial covers this use.
A framework for reading any Follistatin-344 claim
Before treating an online claim about Follistatin-344 as evidence, run it through these four checks:
| Check | Question to ask | What it filters out |
|---|---|---|
| Delivery method | Was the cited study using gene therapy (AAV vector) or the synthetic peptide? | Most positive studies used gene therapy, not the peptide sold online |
| Population | Was it tested in dystrophic/diseased animals, diseased humans, or healthy humans? | Nearly all data is disease-model, not healthy-performance |
| Endpoint | Did the study measure muscle fiber size, functional ambulation, or just biomarker change? | Distinguishes meaningful outcomes from surrogate markers |
| Regulatory status | Is the product FDA-approved, compounded under 503A, or an unregulated research chemical? | Follistatin-344 fails all three as of this writing |
A claim that passes none of these four checks is marketing, not evidence.
When would a clinician actually consider follistatin-based therapy?
Right now, follistatin gene therapy remains investigational and is being studied in the context of specific diagnosed conditions such as Becker muscular dystrophy and inclusion body myositis under research protocols, not as a general muscle-building intervention (Mendell et al., 2015; Mendell et al., 2017). Anyone with a diagnosed muscle-wasting disease considering gene therapy trials should discuss enrollment criteria with a neuromuscular specialist rather than pursue unregulated peptide products, which are a different intervention entirely with none of the same evidence base. Learn more about how these gene therapy programs work on our gene therapy page.
Anyone experiencing unexplained rapid muscle loss, weakness, or wasting should seek an in-person medical evaluation rather than attempt to self-treat with unregulated peptides; these symptoms have many possible causes that require diagnosis, not a myostatin inhibitor.
Bottom line
Follistatin-344 is a real, well-characterized protein with a legitimate and interesting mechanism in muscle biology. The mistake is not in understanding what myostatin inhibition does in a lab. The mistake is assuming that mechanism translates into a safe, effective, injectable consumer product, when the actual evidence base is built almost entirely on gene therapy in diseased animals and small patient cohorts, not on synthetic peptide use by healthy adults.